Results 81 to 90 of about 118,583,499 (297)

Long‐term NSAID efficacy in haematological and bone manifestation of Ghosal haematodiaphyseal dysplasia: An expanded cohort

British Journal of Haematology, EarlyView.
Jonathan Bordat, Felipe Suarez, Matthieu Jestin, Guillaume Bonnard, Joy Benadiba, Stephane Vanderbecken, Thierry Molina, Valérie Cormier‐Daire, Regis Peffault de Latour, Marie Passet, Jean Soulier, Mathilde Doyard, Lise Larcher, Veronique Meignin, Flore Sicre de Fontbrune   +14 more
wiley   +1 more source

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

Haemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini, Robert Klamroth, Bauke Haisma, Dino Mehic, Saskia E. M. Schols   +4 more
wiley   +1 more source

The Hemophilia Registry of the Italian Association of Hemophilia centres

, 2007
Introduction: National Hemophilia registries were found to be powerful instruments to support health care and research. A National Registry was mantained in Italy by the Ministry of Health (ISS) until 1999.
A. Iorio, P. Schinco, M. Morfini, G. Rossetti, M. Schiavoni, A. Scaraggi, A. Tagliaferri, J. Hassan, P. Iannaccaro, A. Gringeri   +9 more
core   +1 more source

Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors

, 2012
Hussain I Saba, Duc Quang Tran, JrDepartment of Medicine, University of South Florida Medical Center, Tampa, FL, USAAbstract: In the past, patients with severe hemophilia have suffered a substantially reduced quality of life with frequent bleeding ...
Tran DQ Jr, Saba HI
core  

MYOCARDIAL INFARCTION AND HEMOPHILIA [PDF]

, 2016
The rare case of myocardial infarction and hemophilia A is presented. Brief review is provided of this issue by literature data.
N. Yu. Stekolshchikova, R. A. Kasimova, A. S. Galyavich, F. I. Mukhamednazarova   +3 more
core   +1 more source

Patient Preferences for the Treatment of Haemophilia A and B in France

Haemophilia, EarlyView.
ABSTRACT Introduction Haemophilia impacts health and quality of life. Advances in treatments such as factor replacement therapy (FRT), bispecific monoclonal antibody (BS‐mAb), gene therapy (GT), rebalancing treatment and high sustained factor necessitate understanding patient preferences to inform therapeutic strategies. Aim This study quantified trade‐
Yesim Dargaud, Yasmine Fahfouhi, Monia Ezzalfani, Astrid Foix Colonier, Alaeddine Sidhom, Aline Gauthier, Jérémie Rudant, Meriem Kessouri, Nicolas Giraud, Benoît Guillet, Anaïs Reynaud   +10 more
wiley   +1 more source

Prosthesis survival situation and complications following total hip arthroplasty in hemophilic patients: a systematic review

BMC Musculoskeletal Disorders
Background Hemophilic arthropathy, resulting from recurrent joint bleeding in patients with hemophilia, often necessitates total hip arthroplasty (THA) to alleviate pain and improve joint function.
Lei Chen, Shineng Lin, Wenlu Zhou, Yiqing Ling, Zhenyu Shi, Qinwen Ge, Wenbin Liu, Ju Li, Peijian Tong, Huihui Li, Taotao Xu   +10 more
doaj   +1 more source

Real‐World Outcomes of Prophylaxis With rIX‐FP in Germany: A Prospective, Non‐Interventional Study in Haemophilia B

Haemophilia, EarlyView.
ABSTRACT Introduction Efficacy and safety of albutrepenonacog alfa (rIX‐FP) in people with haemophilia B (PwHB) has been previously demonstrated in clinical trials. However, real‐world data insights are required. Aim To describe real‐world effectiveness and tolerability of rIX‐FP in PwHB in Germany.
Johannes Oldenburg, Swee Wenning, Susanne Holzhauer, Wolfgang Miesbach, Robert Klamroth, Thomas Linhoff, Patrick Sommerer, Christian Pfrepper, Martin Olivieri, all study investigators   +9 more
wiley   +1 more source

Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects

TH Open, 2019
Background Recombinant (rec-) coagulation factor VIII concentrates available for hemophilia A (HA) treatment differ in cell line production and structure, which could affect their pharmacodynamics and immunogenicity.
Raimondo De Cristofaro, Monica Sacco, Stefano Lancellotti, Federico Berruti, Isabella Garagiola, Carla Valsecchi, Maria Basso, Enrico Di Stasio, Flora Peyvandi   +8 more
doaj   +1 more source

The management of hemophilia in elderly patients

, 2007
Massimo Franchini1, Annarita Tagliaferri2, Pier Mannuccio Mannucci31Transfusion and Hemophilia Center, City Hospital of Verona, Italy; 2Regional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, Italy; 3Angelo Bianchi ...
M. Franchini, P.M. Mannucci, Massimo Franchini, Pier Mannuccio Mannucci, Annarita Tagliaferri, A. Tagliaferri   +5 more
core